Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Gilead_Sciences
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:CEO |
gptkb:Steven_P._James
|
| gptkbp:collaboratesWith |
gptkb:Gilead_Sciences
|
| gptkbp:focus |
immuno-oncology
|
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Max_Krummel
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:products |
PY159
PY314 |
| gptkbp:technology |
Myeloid Tuning
|
| gptkbp:therapeuticArea |
gptkb:immunotherapy
|
| gptkbp:website |
https://www.pionyrtx.com/
|
| gptkbp:bfsParent |
gptkb:Pamela_Klein
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pionyr Immunotherapeutics
|